[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Glaukos Corp (GKOS)

Glaukos Corp (GKOS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Glaukos Announces Participation in Upcoming Investor Conferences

Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases, today announced...

GKOS : 144.01 (+1.31%)
Glaukos: Q1 Earnings Snapshot

Glaukos: Q1 Earnings Snapshot

GKOS : 144.01 (+1.31%)
Glaukos Announces First Quarter 2026 Financial Results

Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases, today announced...

GKOS : 144.01 (+1.31%)
Glaukos Reports Tomorrow With Epioxa Launch Metrics Still Unknown

Barchart Research What to Expect from GKOS Earnings GKOS Generated April 28, 2026 Current Price $119.63 EPS Estimate $$-0.30 Consensus Rating Strong Buy Average Move 9.55% Glaukos Reports Tomorrow With...

GKOS : 144.01 (+1.31%)
Glaukos Announces the Release of its 2025 Sustainability Report

Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases, today announced...

GKOS : 144.01 (+1.31%)
Glaukos Receives Permanent J-code for Epioxaâ„¢

New J-code for Epioxa â„¢ , J2789, set to become effective July 1, 2026

GKOS : 144.01 (+1.31%)
Glaukos to Release First Quarter 2026 Financial Results after Market Close on April 29

Conference Call and Webcast Scheduled for 1:30 p.m. PT

GKOS : 144.01 (+1.31%)
Glaukos to Present Multiple Scientific Abstracts at the 2026 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting

Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases, announced...

GKOS : 144.01 (+1.31%)
Glaukos Announces Commercial Availability of Epioxaâ„¢, a Transformative Innovation in Interventional Keratoconus Care

Epioxa Provides the Ophthalmic Community and Patients with the First and Only FDA-Approved, Incision-Free, Topical Drug Therapy for Keratoconus, a Sight-Threatening Rare Disease

GKOS : 144.01 (+1.31%)
Glaukos: Q4 Earnings Snapshot

Glaukos: Q4 Earnings Snapshot

GKOS : 144.01 (+1.31%)

Barchart Exclusives

Lockheed Martin Stock Looks Well-Positioned to Get a Big Lift From the Very Costly Golden Dome Initiative
LMT stock shows multiple, positive catalysts, with the Golden Dome being among the largest. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.